NASDAQ:ADAPAdaptimmune Therapeutics Stock Price, Forecast & News

Adaptimmune Therapeutics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ADAP shares have increased by 196.6% and is now trading at $8.72.
View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Adaptimmune Therapeutics.

Adaptimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Adaptimmune Therapeutics.

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) issued its quarterly earnings data on Thursday, May, 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.01. The biotechnology company had revenue of $0.76 million for the quarter, compared to analysts' expectations of $25.90 million. Adaptimmune Therapeutics had a negative return on equity of 85.62% and a negative net margin of 7,324.48%.
View Adaptimmune Therapeutics' earnings history.

4 brokers have issued twelve-month price objectives for Adaptimmune Therapeutics' stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Adaptimmune Therapeutics' stock price to reach $7.00 in the next twelve months. This suggests that the stock has a possible downside of 19.7%.
View analysts' price targets for Adaptimmune Therapeutics.

News coverage about ADAP stock has trended neutral this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Adaptimmune Therapeutics earned a media sentiment score of 0.1 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Adaptimmune Therapeutics.

Some companies that are related to Adaptimmune Therapeutics include Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Twist Bioscience (TWST), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), SpringWorks Therapeutics (SWTX), Immunovant (IMVT), Mesoblast (MESO) and Editas Medicine (EDIT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), BlackRock (BLK), Shopify (SHOP), Cara Therapeutics (CARA), Micron Technology (MU) and Chipotle Mexican Grill (CMG).

(ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Adaptimmune Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alps Advisors Inc. (0.16%), Vident Investment Advisory LLC (0.11%), Vident Investment Advisory LLC (0.11%), Leap Investments LP (0.03%), Virtus ETF Advisers LLC (0.03%) and K.J. Harrison & Partners Inc (0.02%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Ali Behbahani, Elliot Norry, Enterprise Associates 14 New, Gavin Wood, Gwendolyn Knowlt Binder-Scholl, James Noble, John Lunger, Lawrence M Alleva, Peter W Sonsini, Rafael Amado and William C Bertrand, Jr.
View institutional ownership trends for Adaptimmune Therapeutics.

ADAP stock was purchased by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Vident Investment Advisory LLC, Vident Investment Advisory LLC, Leap Investments LP, Virtus ETF Advisers LLC, K.J. Harrison & Partners Inc, and Lindbrook Capital LLC. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Ali Behbahani, Enterprise Associates 14 New, Gavin Wood, Lawrence M Alleva, and Peter W Sonsini.
View insider buying and selling activity for Adaptimmune Therapeutics.

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ADAP stock can currently be purchased for approximately $8.72.

Adaptimmune Therapeutics has a market capitalization of $1.13 billion and generates $1.12 million in revenue each year. The biotechnology company earns $-137,160,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe.

The official website for Adaptimmune Therapeutics is www.adaptimmune.com.

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]